Consonance Capital Management LP Karyopharm Therapeutics Inc. Transaction History

Consonance Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$14.14 - $19.71 $91.8 Million - $128 Million	-6,491,812 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$16.6 - $25.25 $11.4 Million - $17.4 Million	-688,888 Reduced 9.59%	6,491,812 $123 Million
Q1 2020 May 15, 2020	BUY	$14.38 - $27.72 $15.1 Million - $29.2 Million	1,053,266 Added 17.19%	7,180,700 $138 Million
Q4 2019 Feb 14, 2020	BUY	$9.23 - $19.67 $2.68 Million - $5.7 Million	290,000 Added 4.97%	6,127,434 $117 Million
Q3 2019 Nov 14, 2019	BUY	$5.66 - $11.85 $193,611 - $405,352	34,207 Added 0.59%	5,837,434 $56.2 Million
Q2 2019 Aug 14, 2019	BUY	$4.32 - $6.43 $2.78 Million - $4.14 Million	644,343 Added 12.49%	5,803,227 $34.8 Million
Q1 2019 May 15, 2019	BUY	$4.12 - $10.25 $1.44 Million - $3.58 Million	348,806 Added 7.25%	5,158,884 $30.1 Million
Q4 2018 Feb 14, 2019	SELL	$8.2 - $16.95 $139,400 - $288,150	-17,000 Reduced 0.35%	4,810,078 $45.1 Million
Q3 2018 Nov 14, 2018	BUY	$17.03 - $21.18 $1.02 Million - $1.27 Million	60,000 Added 1.26%	4,827,078 $82.2 Million
Q2 2018 Aug 14, 2018	BUY	$12.0 - $19.88 $57.2 Million - $94.8 Million	4,767,078 New	4,767,078 $81 Million

111

65.4M

493K

99K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $69.4M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.